Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders

Go back to Defence Therapeutics CEO Highlights Recent Progress and Outlines Strategic Priorities in Letter to Shareholders
(NYSE: DTC) Delayed: 19.55 --0 (-0%)
Previous Close $19.55    52 Week High $ 
Open $19.55    52 Week Low $ 
Day High $19.55    P/E N/A 
Day Low $19.55    EPS $ 
Volume 208,325       

(AMEX: DTCFF) Delayed: 0.29 --0 (-0%)
Previous Close $0.29    52 Week High $ 
Open $0.29    52 Week Low $ 
Day High $0.29    P/E N/A 
Day Low $0.29    EPS $ 
Volume 500